Modulation of Gut Microbiota to Enhance Health and Immunity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04884776|
Recruitment Status : Not yet recruiting
First Posted : May 13, 2021
Last Update Posted : May 13, 2021
|Condition or disease||Intervention/treatment||Phase|
|Gut Microbiota COVID-19 Vaccine||Dietary Supplement: Microbiome immunity formula Dietary Supplement: Active placebo||Not Applicable|
HYPOTHESIS We hypothesize that modulating the gut microbiota with a microbiome immunity formula can rebalance the gut microbiota in populations at risk of infection, like, patients with type 2 DM and elderlies and can lower the number of hospitalisation and reduce side effects associated with COVID-19 vaccination.
AIM We aim to evaluate the efficacy of modulating gut microbiota with a microbiome immunity formula in vulnerable subjects (patients with underlying type 2 DM and elderlies) in improving immune functions, reducing adverse events associated with COVID-19 vaccinations and reducing hospitalisation in susceptible individuals during the COVID-19 pandemic.
STUDY DESIGN This is a double-blinded, randomized, active-placebo controlled study comparing a microbiome immunity formula and placebo in enhancing immunity and reducing hospitalisation within one year. Except two kinds of subjects (Substudy 1: Patients with Type 2 DM and Substudy 2: Elderly individual) will be included in respective substudy, all other methodologies are the same. In each substudy, at least half of the recruited subjects will plan to receive COVID-19 vaccination and start to take the study products after vaccination. Recruited subjects will be randomised to receive a microbiome immunity formula or active placebo for 3 months, with another 9 months follow-up after completion of study products.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||484 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Modulation of Gut Microbiota to Enhance Health and Immunity of Vulnerable Individuals During COVID-19 Pandemic|
|Estimated Study Start Date :||May 10, 2021|
|Estimated Primary Completion Date :||April 26, 2024|
|Estimated Study Completion Date :||April 26, 2024|
Active Comparator: Active arm
Subject will be instructed to take microbiome immunity formula 2 sachets daily for a total of 12 weeks.
Dietary Supplement: Microbiome immunity formula
Microbiome immunity formula contains probiotics blend (3 Bifidobacteria, 10 billion CFU per sachet)
Placebo Comparator: Placebo arm
Subject will be instructed to take active placebo daily for a total of 12 weeks.
Dietary Supplement: Active placebo
Active placebo contains active vitamin
- Restoration of gut dysbiosis [ Time Frame: 3 months ]Proportion of patients achieving restoration of gut dysbiosis at 3 months
- Immunogenicity of the COVID-19 vaccine [ Time Frame: 3 months and 6 months ]Measured by serum neutralization assay against pseudo virus and live virus, and IgM and IgG against receptor-binding domain [RBD] and S1
- Change in gut microbiome [ Time Frame: 1, 3, 6, 9 and 12 months ]Change in gut microbiome
- Changes in plasma inflammatory cytokines [ Time Frame: 3 months and 6 months ]Changes in plasma inflammatory cytokines
- Adverse events [ Time Frame: 12 months ]Adverse events after COVID-19 vaccination
- Number of unscheduled hospitalisation and clinic visits [ Time Frame: 1, 3, 6, 9 and 12 months ]Number of unscheduled hospitalisation and clinic visits
- Changes of quality of life [ Time Frame: 1, 3, 6, 9 and 12 months ]Measured the score of EQ-5D-5L which measure the health-related quality of life
- Changes in glycaemic control [ Time Frame: 3, 6 and 12 months ]Measured by HbA1c
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04884776
|Contact: Joyce WY Mak, FHKAM||3505 firstname.lastname@example.org|
|Contact: Amy Liemail@example.com|
|Prince of Wales Hospital, Shatin|
|Hong Kong, Hong Kong|
|Contact: Joyce WY Mak, FHKAM 3505 3307 firstname.lastname@example.org|
|Principal Investigator:||Joyce WY Mak, FHKAM||Chinese University of Hong Kong|